Skip to main navigation Skip to search Skip to main content

Treatment of gram-negative bacillary meningitis: role of the new cephalosporin antibiotics.

  • C. E. Cherubin
  • , M. L. Corrado
  • , S. R. Nair
  • , M. E. Gombert
  • , S. Landesman
  • , G. Humbert

Research output: Contribution to journalArticlepeer-review

78 Scopus citations

Abstract

Results of the treatment of gram-negative bacillary meningitis have been disappointing: mortality is extremely high, and treatment with chloramphenicol has shown a high failure rate. This failure rate for chloramphenicol is consistent with the wide gap between minimal inhibitory concentration and minimal bactericidal concentration of this drug for Escherichia coli, Klebsiella, and other Enterobacteriaceae. Cefotaxime, a new cephalosporin, is cidal for most gram-negative bacteria at concentrations of less than 0.25 microgram/ml. By late 1981, 137 patients with meningitis due to a variety of bacteria had been treated with this agent. Bacteriologic cure rates were 93% for meningitis due to Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae and 88% for meningitis due to gram-negative bacteria (94.4% for meningitis due to E. coli and Klebsiella). This new antibiotic shows considerable promise in the treatment of these forms of meningitis.

Original languageEnglish
Pages (from-to)S453-464
JournalReviews of Infectious Diseases
Volume4 Suppl
DOIs
StatePublished - 1982

Fingerprint

Dive into the research topics of 'Treatment of gram-negative bacillary meningitis: role of the new cephalosporin antibiotics.'. Together they form a unique fingerprint.

Cite this